RxDoctor Payments DataLook up a doctor →

Jeffrey Kaplan, MD

Neurology · Lenexa, KSNPI 1730176041

Payments from drug & device makers

$4,391,854in general payments, 2019–2025

Across 3,158 payments — averaging $1390.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$884K
  • EMD Serono, Inc.$767K
  • Biogen$621K
  • AbbVie$504K
  • Eli Lilly$471K
  • Amgen$274K
  • plus $872K from 54 others
$35,077in research payments, 2019–2025

Across 11 payments — averaging $3188.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$31K
  • Pfizer$2K
  • Acadia Pharmaceuticals Inc$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis91$883,812
EMD Serono, Inc.661$766,898
Biogen354$620,657
AbbVie(2 entities)549$504,356
Eli Lilly15$470,584
Amgen(2 entities)255$273,830
Mallinckrodt Hospital Products Inc.83$125,293
Sanofi76$102,351
Lilly USA, LLC204$98,557
Roche Products Limited162$90,890
TG Therapeutics, Inc.33$80,978
Genentech, Inc.25$51,171
Teva Pharmaceuticals USA, Inc.191$50,159
Lundbeck LLC90$39,237
Biohaven Pharmaceutical Holding Company Ltd.22$37,392
AstraZeneca(2 entities)56$33,151
H. Lundbeck A S10$32,149
Johnson & Johnson24$23,911
Vanda Pharmaceuticals Inc.24$20,156
Pfizer34$15,697
Adamas Pharmaceuticals, Inc.15$15,254
E.r. Squibb & Sons, L.L.C.11$11,599
Genentech USA, Inc.35$11,314
Bristol Myers Squibb40$9,641
Biohaven Pharmaceuticals, Inc.8$8,304
Impel Pharmaceuticals Inc.4$4,002
Greenwich Biosciences, Inc.2$3,825
Biodelivery Sciences International, Inc.1$3,000
Mallinckrodt Enterprises LLC3$2,165
ANI Pharmaceuticals, Inc.5$153
Tersera Therapeutics LLC6$122
Eisai Inc.5$104
Argenx US, Inc.5$102
Octapharma USA, Inc.6$101
Supernus Pharmaceuticals, Inc.5$81
Acadia Pharmaceuticals Inc7$80
Sanofi-aventis U.S. LLC1$69
Otsuka Pharmaceutical Development & Commercialization, Inc.2$63
Amneal Pharmaceuticals LLC4$60
Grifols USA, LLC3$49
Sandoz3$45
Medtronic2$43
UCB, Inc.3$42
Upsher-smith Laboratories LLC2$41
Banner Life Sciences, LLC2$34
Axsome Therapeutics, Inc.1$31
Bayer1$25
Vertex1$25
Acorda Therapeutics, Inc1$24
Merz Pharmaceuticals, LLC1$20
Novo Nordisk1$20
CSL Behring1$19
Neurelis, Inc.1$18
Cycle Pharmaceuticals Inc1$18
Kedrion Biopharma Inc.2$18
Saol Therapeutics Inc.1$18
Janssen Scientific Affairs, LLC1$17
Kyowa Kirin, Inc.1$17
Hospira, Inc.1$16
Jazz Pharmaceuticals Inc.1$12

How this compares

$4,391,854 in reported general payments places this provider in the 95th percentile of 131 neurology providers in Kansas.

See all neurology providers in Kansas →

Medicare billing

Part B allowed, 2024
$1,195,542
Medicare patients
204
Services billed
74,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Lenexa

See the full list for Kansas →

Where these figures come from

Is this you, or does something look wrong? →